Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Radiation Injuries 2Small Cell Lung Carcinoma 1Pinealoma 1Pain 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1Memory Disorders 1Medulloblastoma 1Lung Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Fatigue 1Ependymoma 1Depression 1Delirium 1Craniopharyngioma 1Cognitive Dysfunction 1Choroid Plexus Neoplasms 1Cancer Pain 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Prednisone 9Pemetrexed 9Epoetin Alfa 9venetoclax 8atezolizumab 8Fentanyl 8Drug Therapy 8Doxorubicin 8Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Donepezil × Clear all
NCT00688376 2022-01-05

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

Eisai Inc.

Phase 3 Completed
72 enrolled 10 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡